VSTM at a glance
Verastem, Inc. (VSTM, SEC CIK 1526119) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Verastem, Inc. (VSTM) reported revenue of $30.9 million (up 209.1% from FY2024) and a net loss of $209.5 million. Diluted EPS was -$3.02.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Verastem, Inc. (VSTM) shares worth $234.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Paterson Dan on November 3, 2026 of 1,299 shares at $9.60 per share.
- In the last 90 days, VSTM insiders reported 0 open-market purchases ($0) and 4 open-market sales ($386K) on Form 4, a net sale of $386K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $30.9M
- +209.1% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$386K
- 13F holders
- 24 funds
- $234.5M · −1 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material risk-factor changes identified, with the 10-Q directing investors to the 2025 Form 10-K
- Cash burn risk: operating cash use increased to $129.6 million from $107.6 million
- Debt interest-rate risk: $75.0 million of Initial Notes carry floating-rate interest
- Market risk: $172.8 million held in cash, equivalents and investments exposed to interest-rate changes
- Foreign-currency risk: CRO and manufacturer contracts may be denominated in foreign currencies
Management Discussion & Analysis
- Quarterly revenue $24.0M, up 114% YoY from $11.2M, driven by AVMAPKI FAKZYNJA CO-PACK shipments
- Product gross margin 84.7% vs 85.1% YoY, based on revenue and product cost figures
- Best growth: VS-7375 clinical R&D $25.9M, up 1891% from $1.3M
- Cash, equivalents and investments $172.8M; operating cash outflow $129.6M vs $107.6M YoY
- Near-term funding through October 2026 offering, expected product revenue and existing resources; FDA blister-pack decision by February 7, 2027
AI summary of the VSTM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Daniel W. Paterson retiring as CEO January 1, 2027, creating a planned leadership transition
- Michael Bailey appointed President and CEO effective January 1, 2027
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation posted November 5, 2026
- Exhibit 99.1 contains the presentation, potentially including updated business and investor information
Item EX-99.1: Item EX-99.1
- Corporate presentation outlines Verastem’s commercial and development strategy in RAS/MAPK-driven cancers
- AVMAPKI FAKZYNJA CO-PACK Q3 net product revenue $24M, with demand steady after Q2 growth
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Daniel W. Paterson retires January 1, 2027, but remains a Class III director through the 2027 annual meeting
- Michael Bailey, 61, becomes president and CEO January 1, 2027, while continuing as Class II director through 2029
Item 8.01: Other Events
- mPDAC efficacy compelling: 41% confirmed ORR in 2L+, 86% DCR, 67% six-month PFS, and 80% six-month OS
- NSCLC signals broad activity: 43% confirmed ORR in 2L+ monotherapy and 75% ORR in 1L combination therapy
Item EX-99.1: Item EX-99.1
- Michael P. Bailey becomes President and CEO January 1, 2027, bringing 30+ years of biopharma experience and 25+ years in oncology
- Daniel Paterson retires after 35 years in biopharma, remaining an advisor and Verastem director, supporting leadership continuity
Item EX-99.3: Item EX-99.3
- VS-7375 shows early efficacy across PDAC, CRC, and NSCLC, supporting Verastem’s strategy to develop a broad KRAS G12D franchise
- PDAC 900mg monotherapy: 41% confirmed ORR, 67% six-month PFS, and 80% six-month OS in 22 patients
Item EX-99.2: Item EX-99.2
- VS-7375 showed 50% confirmed ORR in 2L PDAC and 41% in broader 2L+ disease, supporting a potentially differentiated pancreatic cancer profile
- Two complete responses in 2L+ PDAC, 67% six-month PFS, and 16/22 patients remaining on treatment indicate durable activity
Item 2.02: Results of Operations and Financial Condition
- Preliminary Q3 2026 net product revenue $23.9M-$24.1M, versus $11.2M in Q3 2025
- Revenue roughly doubled year over year, signaling materially stronger product commercialization
Item 7.01: Regulation FD Disclosure
- CEO transition announcement, signaling a leadership change with potential implications for strategy and execution
- Initial efficacy data for VS-7375 from the TARGET-D 101 Phase 1/2 trial in advanced KRAS G12D-mutated solid tumors
AI summaries of VSTM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VSTM
Don't miss the next VSTM filing
- Alerts as it files. A push when VSTM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VSTM, by share count.
- Ask anything. An AI agent that reads every VSTM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Paterson Dan | Sell | Nov 3, 2026 | 1,299 | $9.60 |
| Calkins Daniel | Sell | Oct 1, 2026 | 2,566 | $8.00 |
| Paterson Dan | Sell | Oct 1, 2026 | 44,121 | $8.00 |
| Paterson Dan | A | Sep 30, 2026 | 106,893 | - |
| Calkins Daniel | A | Sep 30, 2026 | 8,333 | - |
| Calkins Daniel | Sell | Sep 21, 2026 | 55 | $7.70 |
| Paterson Dan | Sell | Aug 3, 2026 | 1,302 | $5.81 |
| Calkins Daniel | Sell | Jun 22, 2026 | 4,032 | $4.18 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.0M | $30.9M |
| Operating Income | -$92.1M | -$115.0M | -$170.1M |
| Net Income | -$87.4M | -$130.6M | -$209.5M |
| Op. Margin | - | -1149.6% | -550.3% |
| Net Margin | - | -1306.4% | -677.6% |
| Balance Sheet | |||
| Total Assets | $149.7M | $101.5M | $246.4M |
| Equity | - | -$28.9M | $57.2M |
| ROE | - | 452.1% | -366.2% |
| Per Share | |||
| EPS | $-3.93 | $-3.66 | $-3.02 |
| Cash Flow | |||
| Operating CF | -$86.5M | -$104.8M | -$137.5M |
| CapEx | - | $28K | - |
Source: XBRL data in Verastem, Inc. (VSTM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VSTM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $234.5M |
| Q2 2026 | 25 | $124.5M |
| Q1 2026 | 23 | $138.3M |
| Q4 2025 | 22 | $164.8M |
| Q3 2025 | 21 | $136.9M |
| Q2 2025 | 21 | $53.7M |
| Q1 2025 | 17 | $37.0M |
| Q4 2024 | 13 | $21.1M |
- Morgan Stanley+1.20M (+168%)
- Citigroup+508.2K (+423%)
- BlackRock+323.3K (+4%)
- Raymond James Financial+141.0K (+71%)
- Northern Trust+20.0K (+3%)
- Millennium Management−1.78M (-86%)
- Goldman Sachs Group−1.28M (-47%)
- State Street Corp−1.11M (-22%)
- Vanguard Portfolio Management LLC−710.9K (-22%)
- Citadel Advisors LLC−298.9K (-94%)
- Ameriprise Financial+384.9K
- Renaissance Technologies LLC+34.9K
- FMR LLC (Fidelity)−626.3K
- Dimensional Fund Advisors−235.2K
- Two Sigma Investments−50.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 166 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VSTM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 5, 2026 | - | - | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | May 27, 2026 | - | - | |
| 8-K | May 26, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | May 6, 2026 | - | - | |
| 4 | Mar 23, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VSTM SEC filings: frequently asked questions
Are VSTM insiders buying or selling?
In the last 90 days, Verastem, Inc. (VSTM) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $386,390 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VSTM stock?
As of September 30, 2026, the largest Verastem, Inc. (VSTM) holders among the 13F filers tracked by SignalX were BlackRock ($76.6 million), State Street Corp ($32.4 million), Vanguard Capital Management LLC ($30.7 million), Vanguard Portfolio Management LLC ($20.6 million), Morgan Stanley ($15.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VSTM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Verastem, Inc. (VSTM) reported revenue of $30.9 million (up 209.1% from FY2024) and a net loss of $209.5 million. Diluted EPS was -$3.02. The figures come from the XBRL data in the 10-K.
What did VSTM report in its latest 8-K?
Verastem, Inc. (VSTM) filed an 8-K on November 19, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Daniel W. Paterson retiring as CEO January 1, 2027, creating a planned leadership transition.
What are the latest VSTM SEC filings?
Verastem, Inc. (VSTM) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 5, 2026.
What is VSTM's SEC CIK number?
Verastem, Inc. (VSTM)'s SEC Central Index Key (CIK) is 1526119. EDGAR lists every VSTM filing under that number.
Ask anything about VSTM
The research agent reads VSTM's filings, financials, insider trades and 13F holders, then answers with sources.